These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31574533)

  • 41. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
    Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
    Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 43. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Indian Hedgehog links obesity to development of hepatocellular carcinoma.
    Chong YC; Lim TE; Fu Y; Shin EM; Tergaonkar V; Han W
    Oncogene; 2019 Mar; 38(12):2206-2222. PubMed ID: 30470823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
    Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
    Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
    Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
    Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
    Wang Z; Wei W; Sun CK; Chua MS; So S
    Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
    Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
    Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
    Zhuang R; Zhang X; Lu D; Wang J; Zhuo J; Wei X; Ling Q; Xie H; Zheng S; Xu X
    Mol Carcinog; 2019 Mar; 58(3):366-375. PubMed ID: 30362626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma.
    Jia Q; Xue T; Zhang Q; Cheng W; Zhang C; Ma J; Bu Y; Yu S; Liu Q
    Sci Rep; 2017 Oct; 7(1):13846. PubMed ID: 29061995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
    Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
    Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
    Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
    J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.
    Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF
    J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma.
    Fan M; Shen J; Liu H; Wen Z; Yang J; Yang P; Liu K; Chang Y; Duan J; Lu K
    Oncol Rep; 2017 Aug; 38(2):1083-1090. PubMed ID: 28677793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.